Eton Pharmaceuticals (ETON) Gains from Investment Securities (2017 - 2025)

Eton Pharmaceuticals has disclosed Gains from Investment Securities across 9 years of filings, most recently posting -$1167.0 for Q4 2025.

• Gains from Investment Securities for Q4 2025 came in at -$1167.0, down 100.54% year-over-year; the trailing twelve-month figure through Dec 2025 was $217000.0 (changed 0.0% YoY), and the FY2025 annual result was $5.9 million, changed 0.12% from the prior year.
• Gains from Investment Securities came in at -$1167.0 for Q4 2025 at Eton Pharmaceuticals, down from $6.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $6.3 million in Q2 2024 to a low of -$1167.0 in Q4 2025.
• The 5-year median for Gains from Investment Securities is $551626.0 (2022), against an average of $2.0 million.
• Across the five-year window, Gains from Investment Securities soared 13766.67% in 2021 and slumped 100.54% in 2025, its largest moves.
• Eton Pharmaceuticals' Gains from Investment Securities stood at $3.6 million in 2021, then plunged by 64.46% to $1.3 million in 2022, then sank by 95.99% to $50867.0 in 2023, then jumped by 326.6% to $217000.0 in 2024, then plunged by 100.54% to -$1167.0 in 2025.
• The last three Gains from Investment Securities figures came in at -$1167.0 (Q4 2025), $6.0 million (Q3 2025), and $6.0 million (Q2 2025), per Business Quant data.